• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Med Chem . Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors

tetano

Editor, Senior Moderator
Eur J Med Chem


. 2021 Jan 12;213:113161.
doi: 10.1016/j.ejmech.2021.113161. Online ahead of print.
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors


Mengwu Xiao[SUP] 1 [/SUP], Lvjie Xu[SUP] 2 [/SUP], Ding Lin[SUP] 3 [/SUP], Wenwen Lian[SUP] 2 [/SUP], Manying Cui[SUP] 3 [/SUP], Meng Zhang[SUP] 3 [/SUP], Xiaowei Yan[SUP] 3 [/SUP], Shuishi Li[SUP] 3 [/SUP], Jun Zhao[SUP] 2 [/SUP], Jiao Ye[SUP] 4 [/SUP], Ailin Liu[SUP] 5 [/SUP], Aixi Hu[SUP] 6 [/SUP]



Affiliations

Abstract

A series of 4-thiazolinone derivatives (D1-D58) were designed and synthesized. All of the derivatives were evaluated in vitro for neuraminidase (NA) inhibitory activities against influenza virus A (H1N1), and the inhibitory activities of the five most potent compounds were further evaluated on NA from two different influenza viral subtypes (H3N2 and B), and then their in vitro anti-viral activities were evaluated using the cytopathic effect (CPE) reduction assay. The results showed that the majority of the target compounds exhibited moderate to good NA inhibitory activity. Compound D18 presented the most potent inhibitory activity with IC[SUB]50[/SUB] values of 13.06 μM against influenza H1N1 subtype. Among the selected compounds, D18 and D41 turned out to be the most potent inhibitors against influenza virus H3N2 subtype (IC[SUB]50[/SUB] = 15.00 μM and IC[SUB]50[/SUB] = 14.97 μM, respectively). D25 was the most potent compound against influenza B subtype (IC[SUB]50[/SUB] = 16.09 μM). In addition, D41 showed low toxicity and greater potency than reference compounds Oseltamivir and Amantadine against N1-H275Y variant in cellular assays. The structure-activity relationship (SAR) analysis showed that introducing 4-CO[SUB]2[/SUB]H, 4-OH, 3-OCH[SUB]3[/SUB]-4-OH substituted benzyl methylene can greatly improve the activity of 4-thiazolinones. Further SAR analysis indicated that 4-thiazolinone and ferulic acid fragments are necessary fragments of target compounds for inhibiting NA. Molecular docking was performed to study the interaction between compound D41 and the active site of NA. This study may providing important information for new drug development for anti-influenza virus including mutant influenza virus.

Keywords: 4-Thiazolinone derivatives; Influenza; Neuraminidase inhibitors; Structure-activity relationship; Synthesis.
 
Back
Top Bottom